FDA Issues Complete Response Letter for Galderma's RelabotulinumtoxinA
The US FDA has issued a Complete Response Letter to Galderma for relabotulinumtoxinA, halting the next-generation botulinum toxin's approval pathway pending unresolved deficiencies.